

# Ari Gnanasakthy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2000908/publications.pdf>

Version: 2024-02-01

29  
papers

1,035  
citations

516561

16  
h-index

477173

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1404  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient reported outcomes: looking beyond the label claim. Health and Quality of Life Outcomes, 2010, 8, 89.	1.0	120
2	A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010. Value in Health, 2012, 15, 437-442.	0.1	106
3	Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review. JAMA Oncology, 2015, 1, 375.	3.4	105
4	A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016). Value in Health, 2019, 22, 203-209.	0.1	73
5	Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006-2010). Value in Health, 2013, 16, 1150-1155.	0.1	70
6	Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults. Patient, 2019, 12, 445-459.	1.1	52
7	Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014). Journal of Clinical Oncology, 2016, 34, 1928-1934.	0.8	47
8	Patient-Reported Outcomes, Patient-Reported Information. Patient, 2011, 4, 11-17.	1.1	45
9	Reasons for Rejection of Patient-Reported Outcome Label Claims: A Compilation Based on a Review of Patient-Reported Outcome Use among New Molecular Entities and Biologic License Applications, 2006-2010. Value in Health, 2012, 15, 443-448.	0.1	44
10	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment, 2017, 28, 492-499.	1.1	44
11	A Review of Patient-Reported Outcome Labeling in the United States (2011-2015). Value in Health, 2017, 20, 420-429.	0.1	41
12	US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 441-446.	0.7	40
13	Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment, 2014, 10, 887.	1.0	30
14	Potential of patient-reported outcomes as nonprimary endpoints in clinical trials. Health and Quality of Life Outcomes, 2013, 11, 83.	1.0	29
15	Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology, 2017, 76, 655-661.	0.6	28
16	Measurement Equivalence of Patient-Reported Outcome Measures Migrated to Electronic Formats: A Review of Evidence and Recommendations for Clinical Trials and Bring Your Own Device. Therapeutic Innovation and Regulatory Science, 2019, 53, 426-430.	0.8	22
17	Development of the sporadic inclusion body myositis physical functioning assessment. Muscle and Nerve, 2016, 54, 653-657.	1.0	17
18	Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development. Patient, 2017, 10, 203-213.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Capturing patients' perspectives of treatment in clinical trials/drug development. Contemporary Clinical Trials, 2012, 33, 23-28.	0.8	16
20	Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemporary Clinical Trials, 2013, 35, 62-69.	0.8	16
21	Assessing Changes in Chronic Spontaneous/Ideopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling. Advances in Therapy, 2016, 33, 214-224.	1.3	16
22	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. International Journal of Dermatology, 2016, 55, e147-55.	0.5	14
23	A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility. Value in Health, 2022, 25, 647-655.	0.1	14
24	Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. European Journal of Haematology, 2020, 104, 443-458.	1.1	10
25	Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration-Approved Labeling, 2009 to 2019. Value in Health, 2021, 24, 1016-1023.	0.1	7
26	Role of Patient-Reported Outcome Measures in the Assessment of Central Nervous System Agents. Therapeutic Innovation and Regulatory Science, 2013, 47, 613-618.	0.8	5
27	Overcoming Organizational Challenges of Integrating Patient-Reported Outcomes in Oncology Clinical Trials. Therapeutic Innovation and Regulatory Science, 2015, 49, 822-830.	0.8	4
28	FDA Guidance on Assessment of Patient-Reported Outcomes in Cancer Trials: A Breath of Fresh Air or a Storm in a Teacup?. Patient, 2021, 14, 695-697.	1.1	1
29	Promotion of Patient-Reported Outcome Label Claims Based on Nonprimary Endpoints. Therapeutic Innovation and Regulatory Science, 2014, 48, 557-563.	0.8	0